A detailed history of Regentatlantic Capital LLC transactions in Novo Nordisk A S stock. As of the latest transaction made, Regentatlantic Capital LLC holds 2,345 shares of NVO stock, worth $238,580. This represents 0.01% of its overall portfolio holdings.

Number of Shares
2,345
Previous 2,417 2.98%
Holding current value
$238,580
Previous $269,000 13.01%
% of portfolio
0.01%
Previous 0.01%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2022

Nov 14, 2022

SELL
$95.28 - $116.93 $6,860 - $8,418
-72 Reduced 2.98%
2,345 $234,000
Q2 2022

Aug 15, 2022

BUY
$103.24 - $121.81 $3,303 - $3,897
32 Added 1.34%
2,417 $269,000
Q1 2022

May 02, 2022

BUY
$93.1 - $112.54 $13,034 - $15,755
140 Added 6.24%
2,385 $265,000
Q4 2021

Jan 27, 2022

BUY
$95.88 - $117.08 $15,244 - $18,615
159 Added 7.62%
2,245 $251,000
Q3 2021

Nov 15, 2021

BUY
$84.42 - $106.62 $176,100 - $222,409
2,086 New
2,086 $200,000

Others Institutions Holding NVO

About NOVO NORDISK A S


  • Ticker NVO
  • Exchange OTC
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 2,257,289,984
  • Market Cap $230B
  • Description
  • Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabeti...
More about NVO
Track This Portfolio

Track Regentatlantic Capital LLC Portfolio

Follow Regentatlantic Capital LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Regentatlantic Capital LLC, based on Form 13F filings with the SEC.

News

Stay updated on Regentatlantic Capital LLC with notifications on news.